Stay updated on Clinical Trial: SAR650984 Combo in NDMM Non-Transplant Eligible

Sign up to get notified when there's something new on the Clinical Trial: SAR650984 Combo in NDMM Non-Transplant Eligible page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: SAR650984 Combo in NDMM Non-Transplant Eligible page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the clinical trial study related to the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma not eligible for transplant.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:22.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that researchers are looking for newly diagnosed multiple myeloma patients not eligible for transplant due to age or comorbidities. The criteria now include specific health conditions, prior treatments, and other factors such as organ function and performance status.
    Difference
    9%
    Check dated 2024-05-22T20:57:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:02:09.000Z thumbnail image

Stay in the know with updates to Clinical Trial: SAR650984 Combo in NDMM Non-Transplant Eligible

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: SAR650984 Combo in NDMM Non-Transplant Eligible page.